Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HER2-positive Early Breast Cancer
Status:
Completed
Trial end date:
2017-01-27
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to compare the effectiveness and safety of ABP 980
against trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive
early breast cancer.